tusamitamab ravtansine + gemcitabine

Tusamitamab ravtansine + gemcitabine is an experimental combination regimen under clinical investigation for certain advanced solid tumors, most notably metastatic pancreatic adenocarcinoma. **Tusamitamab ravtansine (SAR408701)** is an antibody-drug conjugate (ADC) comprised of a humanized IgG1 monoclonal antibody targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), a cleavable disulfide linker, and the maytansinoid cytotoxic payload DM4. Upon binding CEACAM5 on tumor cells, the ADC is internalized, releasing DM4 intracellularly, which inhibits microtubule assembly and induces apoptosis. **Gemcitabine** is a standard small molecule chemotherapy agent, a nucleoside analog that inhibits DNA synthesis and induces apoptosis. The combination aims to leverage targeted cytotoxic delivery with the ADC and the antimetabolite effect of gemcitabine. This combination is currently in phase 2 study for CEACAM5-positive metastatic pancreatic adenocarcinoma, with exploration in other CEACAM5+ solid tumors[3][5][7].